Artemisinin Combination Therapy Market Size, Share, and Growth Forecast, 2026 - 2033

The global artemisinin combination therapy market size is likely to be valued at US$0.7 billion in 2026 and is expected to reach US$1.1 billion by 2033, growing at a CAGR of 7.1% between 2026 and 2033, driven by the persistent global burden of malaria, continued procurement of antimalarial medicines through public health programs, and efforts to expand access to effective treatment.

The World Health Organization (WHO) estimated 282 million malaria cases and 610,000 deaths worldwide in 2024. Growing attention to antimalarial drug resistance, improvements in pediatric formulations, and investments in malaria control are expected to influence treatment demand and procurement strategies through 2033.

Artemisinin combination therapies (ACTs) are central to the treatment of uncomplicated Plasmodium falciparum malaria. These medicines combine an artemisinin derivative, which rapidly reduces the number of parasites in the bloodstream, with a partner drug that helps eliminate the remaining parasites.

Drivers - Persistent Global Malaria Burden and the Need for Effective Treatment

The continuing prevalence of malaria remains a fundamental driver of demand for ACTs. WHO estimated 282 million malaria cases and 610,000 deaths worldwide in 2024, representing an increase of approximately 9 million cases compared with 2023. The African Region accounted for approximately 94% of global cases and 95% of deaths, demonstrating the concentration of treatment needs in malaria-endemic countries. These figures reinforce the importance of effective medicines alongside prevention, diagnostic services, surveillance, and timely clinical intervention.

ACTs remain central to treating uncomplicated P. falciparum malaria because combination therapy helps address the limitations associated with relying on a single antimalarial medicine. WHO recommends several ACT regimens, allowing national malaria-control programs to select treatments according to local efficacy evidence and treatment policies. For manufacturers, persistent disease burden supports demand for established products, particularly artemether-lumefantrine. However, actual sales depend on diagnostic coverage, access to healthcare, procurement financing, and the availability of appropriate medicines at treatment facilities.

Public Health Procurement and Expansion of Treatment Access

Government malaria-control programs and international health organizations are important purchasers of ACTs. The Global Fund supports access to recommended antimalarial medicines through its Pooled Procurement Mechanism, helping eligible purchasing programs obtain products through established procurement arrangements. Public-sector purchasing creates opportunities for manufacturers that meet applicable quality standards, maintain adequate production capacity, and offer competitive tender prices.

Demand extends beyond conventional adult tablets to pediatric dispersible formulations, different weight-specific dosage strengths, and medicines used in severe malaria management. Manufacturers with diversified product portfolios can address a wider range of procurement requirements. However, the dependence on public-sector purchasing also exposes suppliers to changes in donor commitments, government budgets, tender schedules, and inventory policies. Reliable delivery, regulatory compliance, and procurement planning are therefore essential competitive advantages in a market where access to treatment and commercial demand depend heavily on institutional purchasing.

Restraint - Antimalarial Drug Resistance and Dependence on Public Funding

Artemisinin partial resistance and declining susceptibility to certain partner drugs present structural challenges for the ACT market. The WHO's 2025 World Malaria Report identified partial resistance to artemisinin derivatives as confirmed or suspected in at least eight African countries, alongside potential signs of reduced efficacy for some partner medicines. Resistance can prompt revisions to national treatment guidelines, increase the need for therapeutic monitoring, and change demand for established drug combinations.

Manufacturers must maintain product quality, monitor changes in treatment recommendations, and ensure that their medicines meet regulatory requirements. At the same time, dependence on public procurement limits pricing flexibility and exposes suppliers to funding interruptions. Companies with limited product portfolios or unreliable active pharmaceutical ingredient supplies may struggle to respond to changes in purchasing specifications. Resistance concerns and procurement uncertainty can constrain profitability even when the underlying clinical need for antimalarial treatment remains high.

Opportunities - Development of Pediatric and Age-Appropriate Formulations

Pediatric formulations present an important opportunity to address treatment gaps among infants and young children. Standard adult-strength medicines can complicate accurate dosing in very small infants, while dispersible tablets improve administration for children who cannot swallow conventional tablets. In April 2026, Novartis announced that WHO had prequalified Coartem Baby, an artemether-lumefantrine formulation developed for newborns and young infants weighing 2-5 kg.

This development demonstrates how formulation innovation can expand the range of patients who can receive appropriately designed ACT products. Manufacturers that offer accurate weight-based dosing, practical administration, and dependable supply may be better positioned to participate in public health procurement programs. Commercial opportunities will depend on national registration, procurement commitments, affordability, and inclusion in relevant treatment policies. Investment in pediatric formulations may also strengthen a supplier's broader position in markets where children represent a substantial share of the malaria treatment burden.

Treatment Diversification and Resistance Management

Growing concern about antimalarial drug resistance is increasing attention to treatment diversification and the development of alternative medicines. WHO guidance on multiple first-line therapies encourages eligible malaria programs to consider using more than one effective ACT as part of efforts to reduce reliance on a single treatment regimen. This approach creates opportunities for manufacturers offering several quality-assured combinations, including artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and DHA-PPQ.

Research into new treatment options also remains important. In November 2025, Novartis reported positive Phase III results for ganaplacide/lumefantrine, an investigational treatment intended to address challenges associated with antimalarial resistance. Although the medicine remains distinct from established, routinely recommended ACT products, the results demonstrate continued investment in treatment innovation. Manufacturers that maintain diversified portfolios and monitor national treatment guidelines can respond more effectively to changes in clinical requirements and procurement preferences.

Drug Combination Insights

Artemether-lumefantrine is anticipated to account for 43.5% of the market share in 2026, supported by its established role in national malaria programs, broad generic availability, and multiple dosage formats. For example, Novartis supplies Coartem, while manufacturers such as Cipla and Ipca Laboratories serve antimalarial markets with relevant formulations. Conventional and dispersible tablets support treatment across different age and weight groups, including pediatric patients.

Dihydroartemisinin-piperaquine is anticipated to be the fastest-growing segment, with a projected CAGR of 9.3%. Its once-daily dosing during treatment and piperaquine’s longer post-treatment prophylactic effect may support uptake where national guidelines recommend its use. Guilin Pharmaceutical is an example of a supplier in the antimalarial market. Growth remains dependent on local parasite susceptibility, product registration, treatment guidelines, and public procurement decisions. Other ACT combinations also provide alternatives for markets with differing clinical requirements.

Malaria Type Insights

Uncomplicated P. falciparum malaria treatment is anticipated to hold a leading 60.4% share of market revenue in 2026. Oral ACTs are standard treatments under WHO guidance, with artemether-lumefantrine and artesunate-amodiaquine among the relevant options. Demand depends on malaria incidence, access to rapid diagnostic tests, timely treatment, and the availability of quality-assured medicines through government programs, clinics, and community health facilities.

Severe malaria management is anticipated to be the fastest-growing application. Severe cases require urgent treatment, with injectable artesunate recommended as the preferred initial therapy, followed by a complete course of an appropriate oral ACT once the patient can tolerate oral medication. For example, hospitals may use injectable artesunate for acute management before transitioning patients to oral artemether-lumefantrine. This creates related demand across hospital-based severe-malaria treatment and follow-on ACT therapy, although injectable artesunate and oral ACTs remain distinct product categories.

North America Artemisinin Combination Therapy Market Trends

North America represents a specialized market for artemisinin combination therapy (ACT), with an anticipated share of 41.3% of market value in 2026, driven mainly by imported malaria cases, hospital treatment, and pharmaceutical regulatory requirements rather than endemic transmission. Demand remains limited compared with malaria-endemic regions, making medicine availability and clinical protocols more influential than large-scale public procurement.

U.S. Artemisinin Combination Therapy Market Trends

The U.S. reports approximately 2,000 malaria cases annually, most associated with international travel. Coartem, Novartis’s artemether-lumefantrine brand, is the preferred treatment for most uncomplicated malaria cases under current CDC guidance. In August 2026, the CDC updated its recommendations to extend artemether-lumefantrine treatment for P. falciparum malaria to five days. The guidance also applies the extended regimen when the medicine is used following intravenous artesunate for severe infections. This change increases the importance of treatment protocols, medicine availability, and course-level supply planning for hospitals and distributors.

Canada Artemisinin Combination Therapy Market Trends

Canada also requires reliable antimalarial supplies for travelers and other patients returning from endemic countries. Its demand is concentrated in diagnostic laboratories, hospitals, and specialist infectious-disease services. Unlike endemic markets, where national programs purchase medicines in substantial volumes, Canadian demand depends more on imported cases and institutional preparedness. Suppliers must maintain suitable distribution arrangements to ensure access to appropriate treatments when cases occur.

Europe Artemisinin Combination Therapy Market Trends

Europe is a comparatively small ACT consumption market because malaria transmission has been eliminated from most countries. Demand primarily arises from international travel, migration, and treatment of imported infections. Regulatory compliance, specialist hospital access, and dependable medicine distribution shape commercial opportunities more strongly than large recurring malaria-control tenders.

The region’s pharmaceutical infrastructure supports the management of uncomplicated and severe malaria, but low case volumes limit opportunities for substantial consumption growth. Manufacturers therefore rely on authorized supply arrangements and hospital procurement rather than broad consumer distribution. Europe’s role in the ACT market also extends to pharmaceutical development and collaboration with global health organizations.

U.K. Artemisinin Combination Therapy Market Trends

The U.K. uses Riamet, an artemether-lumefantrine brand, for uncomplicated P. falciparum malaria. U.K. surveillance has documented suspected treatment failures and recurrences, prompting continued attention to follow-up and alternative treatment where clinically indicated. National guidance also recognizes Eurartesim, a dihydroartemisinin-piperaquine combination. These options support clinical choice, while low case volumes limit large-scale market expansion.

France Artemisinin Combination Therapy Market Trends

France’s ACT demand is largely linked to imported malaria and specialist treatment. Across the European Union, Eurartesim, marketed by Alfasigma, is authorized for uncomplicated P. falciparum malaria in eligible adults and children. Its once-daily, three-day treatment course provides an alternative to artemether-lumefantrine, subject to clinical suitability and product availability. European sales remain dependent on hospital procurement and distribution rather than mass public-health tenders.

Asia Pacific Artemisinin Combination Therapy Market Trends

Asia Pacific is anticipated to be the fastest-growing regional market in the supplied forecast. Its outlook reflects persistent malaria-treatment needs in selected endemic countries and a well-established manufacturing base. Nevertheless, falling case numbers in some markets can offset growth elsewhere, making country-level disease trends and procurement policies essential considerations.

India Artemisinin Combination Therapy Market Trends

India plays a dual role as a malaria-treatment market and a major antimalarial manufacturing base. Companies including Cipla, Ipca Laboratories, Macleods Pharmaceuticals, Ajanta Pharma, and Strides Pharma Science supply ACT products listed by the World Health Organization as prequalified medicines. Examples include Cipla’s and Ipca’s dispersible artemether-lumefantrine tablets and Ipca’s injectable artesunate. These products support treatment across pediatric and adult populations, while WHO prequalification can facilitate procurement by international agencies and eligible public-health programs.

India’s declining malaria burden creates a mixed market outlook: domestic demand may become more geographically concentrated, while qualified manufacturers can pursue export and institutional procurement opportunities. Product quality, competitive pricing, regulatory compliance, and reliable delivery remain central to commercial performance.

China Artemisinin Combination Therapy Market Trends

China contributes to regional supply through Guilin Pharmaceutical, which manufactures antimalarial medicines, including artesunate and dihydroartemisinin-piperaquine products. Its WHO-prequalified product portfolio includes DHA-PPQ tablets and dispersible formulations. Such offerings expand supplier options for procurement programs serving endemic markets, although purchasing depends on national treatment guidelines and local parasite susceptibility. China’s malaria-free status means its commercial importance lies more in manufacturing and international supply than in domestic treatment volumes.

The global artemisinin combination therapy market includes multinational pharmaceutical companies, generic manufacturers, specialist antimalarial suppliers, and active pharmaceutical ingredient producers. Competition is shaped by product quality, WHO prequalification, national registrations, tender pricing, manufacturing capacity, and dependable supply rather than brand recognition alone.

Leading suppliers compete through cost-efficient manufacturing, quality-assured products, broad ACT portfolios, and reliable tender delivery. Formulation innovation, particularly pediatric products, provides differentiation where treatment access remains constrained. Geographic expansion depends on national registration, distribution partnerships, and procurement qualification. Companies with multiple approved combinations and dependable active pharmaceutical ingredient supplies can respond more flexibly to changes in treatment guidelines and public purchasing requirements.

Key Industry Developments

• In September 2026, the World Health Organization updated its malaria guidelines to include recommendations for a new artemether-lumefantrine formulation for children weighing less than 5 kg.
• In April 2026, Novartis announced that Coartem Baby (artemether-lumefantrine) received WHO prequalification for treating uncomplicated malaria in newborns and young infants weighing 2-5 kg.